BR0015294A - Método para tratamento da diabetes - Google Patents

Método para tratamento da diabetes

Info

Publication number
BR0015294A
BR0015294A BR0015294-3A BR0015294A BR0015294A BR 0015294 A BR0015294 A BR 0015294A BR 0015294 A BR0015294 A BR 0015294A BR 0015294 A BR0015294 A BR 0015294A
Authority
BR
Brazil
Prior art keywords
diabetes
treating diabetes
employing
treating
treatment
Prior art date
Application number
BR0015294-3A
Other languages
English (en)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0015294A publication Critical patent/BR0015294A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO PARA TRATAMENTO DA DIABETES". é providenciado um método para tratamento de primeira linha da diabetes tipo 2 empregando uma combinação de metformina e gliburida. Também se providencia um método para tratamento da diabetes em pacientes humanos não consumidores da droga empregando a formulação acima no sentido de reduzir a resistência à insulina e/ou excursão da glicose pós-prandial e/ou hemoglobina 1Ac, e/ou aumento da insulina pós-prandial, tratando assim, a diabetes.
BR0015294-3A 1999-11-03 2000-10-13 Método para tratamento da diabetes BR0015294A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
PCT/US2000/028311 WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
BR0015294A true BR0015294A (pt) 2003-07-15

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015294-3A BR0015294A (pt) 1999-11-03 2000-10-13 Método para tratamento da diabetes

Country Status (23)

Country Link
EP (1) EP1229918B1 (pt)
JP (1) JP5183844B2 (pt)
KR (1) KR20070089259A (pt)
CN (1) CN1450902A (pt)
AR (1) AR026356A1 (pt)
AT (1) ATE390140T1 (pt)
AU (1) AU780106B2 (pt)
BR (1) BR0015294A (pt)
CA (1) CA2389928C (pt)
EE (1) EE05260B1 (pt)
HU (1) HU229352B1 (pt)
IL (1) IL149139A0 (pt)
LT (1) LT5058B (pt)
LV (1) LV12910B (pt)
MX (1) MXPA02004282A (pt)
NO (1) NO330026B1 (pt)
NZ (1) NZ518278A (pt)
PL (1) PL199278B1 (pt)
RU (1) RU2275915C2 (pt)
SK (1) SK287810B6 (pt)
TW (1) TWI280125B (pt)
UY (1) UY26424A1 (pt)
WO (1) WO2001032157A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
IL164222A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
AU2004288641B2 (en) * 2003-10-30 2010-08-12 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
JP4845740B2 (ja) * 2003-12-19 2011-12-28 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 糖尿病を治療するための組成物および方法
EP1744737A2 (en) * 2004-05-03 2007-01-24 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
NZ583346A (en) 2007-07-19 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and metformin hydrochloride
CA2699285C (en) 2007-09-10 2016-12-13 Ahmed F. Abdel-Magid Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
BR112012011128A2 (pt) 2009-11-13 2016-07-05 Sanofi Aventis Deutschland composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
UY33380A (es) 2010-05-11 2011-12-01 Janssen Pharmaceutica Nv Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos
KR101823320B1 (ko) 2010-08-30 2018-01-31 사노피-아벤티스 도이칠란트 게엠베하 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
KR20140041409A (ko) * 2011-02-02 2014-04-04 사노피-아벤티스 도이칠란트 게엠베하 ２형 진성 당뇨병 환자에서 저혈당증의 예방
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
JP2002504137A (ja) 1997-06-18 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
UY26424A1 (es) 2001-05-31
AU780106B2 (en) 2005-03-03
EE200200242A (et) 2003-12-15
NO20022087D0 (no) 2002-05-02
IL149139A0 (en) 2002-11-10
CA2389928C (en) 2010-03-23
WO2001032157A3 (en) 2002-01-24
HUP0300218A2 (hu) 2003-06-28
WO2001032157A2 (en) 2001-05-10
RU2275915C2 (ru) 2006-05-10
EP1229918A2 (en) 2002-08-14
SK287810B6 (sk) 2011-10-04
CN1450902A (zh) 2003-10-22
HUP0300218A3 (en) 2006-02-28
NO20022087L (no) 2002-06-24
SK5002002A3 (en) 2004-05-04
JP5183844B2 (ja) 2013-04-17
ATE390140T1 (de) 2008-04-15
JP2003519621A (ja) 2003-06-24
NO330026B1 (no) 2011-02-07
LT5058B (lt) 2003-09-25
LV12910B (en) 2003-05-20
TWI280125B (en) 2007-05-01
CA2389928A1 (en) 2001-05-10
MXPA02004282A (es) 2003-02-17
LT2002063A (en) 2003-06-25
KR20070089259A (ko) 2007-08-30
EP1229918B1 (en) 2008-03-26
NZ518278A (en) 2004-10-29
AU1082601A (en) 2001-05-14
EE05260B1 (et) 2010-02-15
RU2002114820A (ru) 2004-03-10
PL199278B1 (pl) 2008-09-30
AR026356A1 (es) 2003-02-05
PL364885A1 (en) 2004-12-27
HU229352B1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
BR0015294A (pt) Método para tratamento da diabetes
TNSN00206A1 (en) Method for treating diabetes
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
BRPI0417829A (pt) composições e processos para tratamento da diabetes
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
BR0212512A (pt) Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
BR9916279A (pt) Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos
DK403188D0 (da) Piperazinylpurin og fremgangsmaade til fremstilling deraf
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
AR025449A1 (es) Soluciones farmaceuticas de levosimendan
BR9814075A (pt) Método de tratamento da doença de alzheimer
SE0102147D0 (sv) New methods
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR9610481A (pt) Agonistas adrenérgicos beta seletivos
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
BRPI0413481A (pt) cascas de lêvedos para o tratamento ou a prevenção da hiperglicemia ou para a estabilização da glicemia
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 10(VIII) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.